Gynecologic Oncology Consult

Telling her she has cancer: A patient-centered approach to breaking bad news


 

The aftermath

That interval between initial diagnosis and specialist consultation is extraordinarily difficult and a high anxiety time. It is not unreasonable, in such cases, to recommend the patient to reputable online information sources, such as the Society of Gynecologic Oncology or American Cancer Society websites so that she and her family can do some research prior to that visit in order to prepare them better and give them a sense of understanding in their disease.

It is a particularly compassionate touch to reach out to the patient in the days following her cancer diagnosis, even if she has moved on to a specialist. Patients often tell me that they felt enormous reassurance and appreciation when their ob.gyn. reached out to them to “check on how they are doing.” This can usually reasonably be done by phone. This second contact serves another critical purpose: it allows for repetition of the diagnosis and initial plan, and the ability to fill in the blanks of what the patient may have missed during the prior visit, if her mind was, naturally, elsewhere. It also, quite simply, shows that you care.

Dr. Emma C. Rossi is an assistant professor in the division of gynecologic oncology at UNC-Chapel Hill.

Dr. Emma C. Rossi


Ultimately, none of us can break bad news perfectly every time. We all need to be insightful with each of these encounters as to what we did well, what we did not, and how we can adjust in the future. With respect to the SPIKES approach, patients report that physicians struggle most with the “perception,” “invitation,” and “strategy and summary” components.5 Our objective should be keeping the patient’s needs in mind, rather than our own, to maximize the chance of doing a good job. If this task is done well, not only are patients more likely to have positive emotional adjustments to their diagnosis but also more adherence with future therapies.4 In the end, it is the patient who has the final say on whether it was done well or not.

Dr. Rossi is an assistant professor in the division of gynecologic oncology at the University of North Carolina at Chapel Hill. She reports no relevant financial disclosures.

References

1. Baile WF et al. Oncologist. 2000;5(4):302-11.

2. Girgis A et al. Behav Med. 1999 Summer;25(2):69-77.

3. Schmid MM et al. Patient Educ Couns. 2005 Sep;58(3):244-51.

4. Girgis A et al. J Clin Oncol. 1995 Sep;13(9):2449-56.

5. Marscholiek P et al. J Cancer Educ. 2018 Feb 5. doi: 10.1007/s13187-017-1315-3.

Pages

Recommended Reading

Deep infiltrating endometriosis lesions harbor cancer-driver mutations
MDedge Internal Medicine
FDA okays pembrolizumab for certain solid tumors with common biomarker
MDedge Internal Medicine
As government-funded cancer research sags, scientists fear U.S. is ‘losing its edge’
MDedge Internal Medicine
Is pain or dependency driving elevated opioid use among long-term cancer survivors?
MDedge Internal Medicine
FDA approves biosimilar to bevacizumab
MDedge Internal Medicine
Missed opportunities abound to give HPV vaccine to adolescent girls
MDedge Internal Medicine
Adolescents with chronic health conditions often undervaccinated
MDedge Internal Medicine
FDA: Laparoscopic power morcellators can spread malignant cells when used in women with occult uterine cancers*
MDedge Internal Medicine
New multi-analyte blood test shows promise in screening for several common solid tumors
MDedge Internal Medicine
USPSTF: Routine screens for ovarian cancer not recommended
MDedge Internal Medicine